Specifically, the combined treatment showed a remarkable antitumor effect by dramatically reducing tumor growth and large aberrant crypts loci via Wnt pathway, by decreasing β-catenin, NF-κβ, COX-2, iNOS, VEGF and HSP-90 and increasing DKK-1, CDNK-1A, TGF-β1, TGF-β/RII, smad4 and GPx in the early stage of CRC [117,118]. The gene discussed is TGFB1; the disease is colorectal carcinoma.